[go: up one dir, main page]

WO1998027113A8 - Melanocortines - Google Patents

Melanocortines

Info

Publication number
WO1998027113A8
WO1998027113A8 PCT/NL1997/000703 NL9700703W WO9827113A8 WO 1998027113 A8 WO1998027113 A8 WO 1998027113A8 NL 9700703 W NL9700703 W NL 9700703W WO 9827113 A8 WO9827113 A8 WO 9827113A8
Authority
WO
WIPO (PCT)
Prior art keywords
melanocortin
derivatives
specific binding
receptor
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL1997/000703
Other languages
English (en)
Other versions
WO1998027113A3 (fr
WO1998027113A2 (fr
WO1998027113A9 (fr
Inventor
Roger Antonius Hendricus Adan
Johannes Peter Henri Burbach
Willem Hendrik Gispen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Holdings Cambridge Ltd
Original Assignee
Quadrant Holdings Cambridge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Holdings Cambridge Ltd filed Critical Quadrant Holdings Cambridge Ltd
Priority to CA002275442A priority Critical patent/CA2275442A1/fr
Priority to EP97950498A priority patent/EP0946595A2/fr
Priority to JP52756598A priority patent/JP2001506996A/ja
Priority to AU53480/98A priority patent/AU5348098A/en
Publication of WO1998027113A2 publication Critical patent/WO1998027113A2/fr
Publication of WO1998027113A3 publication Critical patent/WO1998027113A3/fr
Anticipated expiration legal-status Critical
Publication of WO1998027113A8 publication Critical patent/WO1998027113A8/fr
Publication of WO1998027113A9 publication Critical patent/WO1998027113A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention concerne de nouveaux peptides dérivés du groupe d'hormones comprenant l'ACTH. Ces peptides, ou 'mélanocortines' (connus autrefois sous le nom de 'mélanotropines'), sont capables de cibler différents récepteurs se localisant souvent différemment sur plusieurs tissus. Les peptides de la présente invention conviennent particulièrement au ciblage agoniste de récepteurs du système nerveux. L'invention concerne également des compositions pharmaceutiques et leur utilisation.
PCT/NL1997/000703 1996-12-17 1997-12-17 Melanocortines Ceased WO1998027113A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002275442A CA2275442A1 (fr) 1996-12-17 1997-12-17 Melanocortines
EP97950498A EP0946595A2 (fr) 1996-12-17 1997-12-17 Melanocortines
JP52756598A JP2001506996A (ja) 1996-12-17 1997-12-17 メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体
AU53480/98A AU5348098A (en) 1996-12-17 1997-12-17 Melanocortins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96203567.1 1996-12-17
EP96203567 1996-12-17

Publications (4)

Publication Number Publication Date
WO1998027113A2 WO1998027113A2 (fr) 1998-06-25
WO1998027113A3 WO1998027113A3 (fr) 1998-08-06
WO1998027113A8 true WO1998027113A8 (fr) 1999-09-02
WO1998027113A9 WO1998027113A9 (fr) 1999-11-04

Family

ID=8224709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1997/000703 Ceased WO1998027113A2 (fr) 1996-12-17 1997-12-17 Melanocortines

Country Status (6)

Country Link
EP (1) EP0946595A2 (fr)
JP (1) JP2001506996A (fr)
CN (1) CN1246868A (fr)
AU (1) AU5348098A (fr)
CA (1) CA2275442A1 (fr)
WO (1) WO1998027113A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1213020E (pt) * 1997-04-15 2009-04-24 Csir Compostos e composições farmacêuticas com actividade supressora do apetite
IL145406A0 (en) 1999-03-29 2002-06-30 Procter & Gamble Melanocortin receptor ligands
WO2003006620A2 (fr) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Peptides lineaires et cycliques specifiques du recepteur de melanocortine
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
WO2001030808A1 (fr) * 1999-10-27 2001-05-03 The Regents Of The University Of California Procedes et composes utiles pour moduler la liaison du recepteur de melanocortine-ligand
WO2001052880A1 (fr) 2000-01-18 2001-07-26 Merck & Co., Inc. Peptides cycliques utilises comme antagonistes puissants et selectifs du recepteur de la melanocortine-4
GB0012370D0 (en) * 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
WO2005030797A2 (fr) 2003-09-30 2005-04-07 Novo Nordisk A/S Nouveaux agonistes du recepteur de la melanocortine
EP1708755B1 (fr) 2004-01-21 2012-03-21 Novo Nordisk Health Care AG Conjugaison de peptides induite par la transglutaminase
MX2010013436A (es) 2008-06-09 2011-06-21 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de disfuncion sexual.
NZ596617A (en) 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (fr) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
KR20120102716A (ko) 2009-11-23 2012-09-18 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴-1 수용체 특이적 선형 펩티드
WO2011063366A1 (fr) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Peptides cycliques spécifiques du récepteur de la mélanocortine-1
EP2513096A1 (fr) 2009-12-18 2012-10-24 Janssen Pharmaceutica, N.V. Aminothiazolone indazoles substitués comme modulateurs des récepteurs alpha liés aux strogènes
JP2013519730A (ja) 2010-02-17 2013-05-30 ヤンセン ファーマシューティカ エヌ．ベー． エストロゲン関連受容体α変調剤としてのアミノチアゾロン
RU2012139459A (ru) 2010-02-17 2014-03-27 Янссен Фармацевтика Нв Аминотиазолоны для использования в качестве модуляторов родственных эстрогену рецепторов альфа
EP2539364A1 (fr) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides de traitement de l'obésité
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
WO2011149841A1 (fr) 2010-05-25 2011-12-01 Janssen Pharmaceutica Nv Thiazolidinedione indazoles, indoles et benzotriazoles substitués utiles en tant que modulateurs des récepteurs α liés aux œstrogènes
EP2944650A1 (fr) 2012-10-19 2015-11-18 TXP Pharma GmbH Analogues alpha- et gamma-MSH
RU2016142145A (ru) 2014-04-22 2018-05-22 ТиЭксПи ФАРМА ГМБХ Пептидные аналоги с разветвленным аминокислотным зондом (зондами)
EP3596107A1 (fr) 2017-03-15 2020-01-22 Novo Nordisk A/S Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69429768T2 (de) * 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen

Also Published As

Publication number Publication date
WO1998027113A3 (fr) 1998-08-06
CA2275442A1 (fr) 1998-06-25
CN1246868A (zh) 2000-03-08
AU5348098A (en) 1998-07-15
WO1998027113A2 (fr) 1998-06-25
EP0946595A2 (fr) 1999-10-06
WO1998027113A9 (fr) 1999-11-04
JP2001506996A (ja) 2001-05-29

Similar Documents

Publication Publication Date Title
WO1998027113A8 (fr) Melanocortines
WO1999033859A3 (fr) Nouveaux steroides anti-oestrogenes, compositions pharmaceutiques associees et leur mode d'utilisation
ZA9711537B (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
EP1715040A3 (fr) Domaines des doigts de zinc pour GNN
WO1998005363A3 (fr) Polypeptides possedant un polymere soluble dans l'eau a n-terminal lie par covalence simple
EP1803733A3 (fr) Traitement de l'inflammation
CA2383926A1 (fr) Genomique fonctionnelle utilisant des proteines a doigts de zinc
WO2002047671A3 (fr) Composé de lactam
WO2001083547A3 (fr) Composes anti-inflammatoires et leurs utilisations
WO1998018497A3 (fr) Agents de contraste
HUP0100270A3 (en) Peptids for inhibiting betha-amyloid peptide release and/or its synthesis, pharmaceutical compositions comprising thereof and their use
WO1996037605A3 (fr) OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE
WO2001023412A3 (fr) Procedes de criblage d'agents inhibiteurs de l'agregation des polypeptides
WO2003002602A3 (fr) Peptides nogo et derivees du recepteur nogo pour la neuroprotection induite par les lymphocytes t
AUPP589598A0 (en) Novel peptides
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
WO1998058957A3 (fr) Analogues d'hormones glycoproteiques a liaison reticulee disulfite, preparation et utilisation
WO2000018801A3 (fr) Composes se liant aux n-cam
WO2000042031A3 (fr) Heterocycles 2-arylimino substitues et compositions les contenant, utilisables comme agents de liaison des recepteurs de progesterone
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
EP0784979A3 (fr) Formulations contenant une protéine de l'obésité
WO1999031128A3 (fr) Proteines du type facteur humain de necrose tumorale r2
EP1333093A3 (fr) NAD:arginine ADP-ribosiltransferase du muscle humain
WO2000052045A3 (fr) Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
EP0784982A3 (fr) Préparation des protéines contre l'obésité

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181332.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref document number: 2275442

Country of ref document: CA

Ref document number: 2275442

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997950498

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 1998 527565

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 53480/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09331287

Country of ref document: US

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 25/98 UNDER (30) REPLACE "AT" BY "EP"

WWP Wipo information: published in national office

Ref document number: 1997950498

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 2-6 AND 8-10, DESCRIPTION, REPLACED BY CORRECTED PAGES 2-6 AND 8-10; PAGES 11 AND 12, CLAIMS, REPLACED BY CORRECTED PAGES 11 AND 12

WWW Wipo information: withdrawn in national office

Ref document number: 1997950498

Country of ref document: EP